Marc D. Beer, Chief Executive Officer at Aegerion Pharmaceuticals, Inc. (AEGR), sold 40,000 shares at $93.00 ($3.5M) on 2013-10-30, disclosed to the SEC on 2013-10-31.
Scheduled sale ($3.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $84.15 | 2,800 | $236K | 6.7% |
| 2 | $85.00 | 7,067 | $601K | 17.1% |
| 3 | $85.94 | 2,314 | $199K | 5.7% |
| 4 | $87.08 | 10,000 | $871K | 24.8% |
| 5 | $87.83 | 6,019 | $529K | 15.1% |
| 6 | $89.01 | 3,800 |
| $338K |
| 9.6% |
| 7 | $89.85 | 2,700 | $243K | 6.9% |
| 8 | $91.21 | 2,500 | $228K | 6.5% |
| 9 | $92.03 | 700 | $64K | 1.8% |
| 10 | $93.00 | 400 | $37K | 1.1% |
| 11 | $94.25 | 200 | $19K | 0.5% |
| 12 | $95.90 | 300 | $29K | 0.8% |
| 13 | $99.18 | 1,200 | $119K | 3.4% |
| Total | $87.79 avg | 40,000 | $3.5M | 100% |
| Filing → |
| BTMD | SELL | 2023-01-10 | $2.6M | — | Filing → |
| NERV | BUY | 2017-03-21 | $406K | — | Filing → |
| AEGR | BUY | 2014-07-31 | $337K | — | Filing → |